GSK to pay Chimagen $300m upfront to develop autoimmune drug
GSK Plc., will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
GSK Plc., will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.
British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an.
Summit Therapeutics Inc.’s investigational drug ivonescimab helps lung cancer patients to cut the risk of progression or death from the disease by 48%,.
Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated.
The US-based Merck and Co.’s investigational medicine to protect infants from respiratory syncytial virus (RSV) disease has resulted in lowering infections, according to.
US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.